Pantec Biosolutions AG (Switzerland) - Dec 2007

unquote
01 December 2007

Tweet
Facebook
LinkedIn
Google plus
Send to

Gamma Capital Partners has led a CHF 6.3m Series A investment round in drug delivery company Pantec Biosolutions, with finance drawn from the firm’s Luxembourg-based fund, Gamma III SICAR. This investment is complemented by investments from a group of private investors from various industries in Switzerland, Austria, Germany and Liechtenstein.

The investor was impressed with the experience and entrepreneurial drive of the company founders and executive team, the fast and effective execution of the project since its inception and the scope of the company’s drug delivery platform and the market opportunity that it presents.

This new investment will enable Pantec Biosolutions to further develop its device and drug patch technology with the aim of replacing the required hormone treatment regime of daily injections made over a period of several weeks during in vitro fertilisation, with a simpler regime of epidermal preparation and hormone patches. The company’s current business model is focused on developing a variety of therapeutic treatments which encompass the IVF therapy regime.

Company

Pantec Biosolutions AG is a private drug delivery company specialising in laser micro-poration technology for the transdermal delivery of large molecular weight drugs into the epidermis for systemic or topical uptake, removing unwanted therapeutic side effects including drug degradation. Its proprietary LEDDT platform enables efficient, needle free and painless application of biopharmaceutical drugs, such as IVF hormones, in varying and individualised dosages through partnered patch technology.

Pantec Biosolutions has developed a trademarked laser micro-poration device called LEDDT (Laser Easy Drug Delivery Technology) for large molecular weight drug delivery such as IVF hormones, placing the company in a strong position for later-stage licensing or its own commercialisation. Pantec Biosolutions has also developed a preclinical pipeline of identified biopharmaceutical therapies for LEDDT transdermal application to resolve unmet medical needs in selected therapeutic areas. The company’s LEDDT platform is available both for the development of the company’s own pipeline and for penetration into new markets through strategic partnerships. The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of $1.5-2bn. Pantec Biosolutions is based in Ruggell, Liechtenstein.

People

Burkhard Feurstein represented Gamma Capital Partners AG.

Sourced from: Deutsche unquote" 95 (Feb 2008)